胃肠间质瘤伊马替尼辅助治疗新进展

在靶向药物出现之前,完整手术切除是胃肠间质瘤(GIST)的惟一潜在治愈方法。然而8,5%高危型患者在术后出现复发、转移,5年无复发生存率约20%～40%。甲磺酸伊马替尼(imatinib mesylate,IM)作为靶向抑制酪氨酸激酶活性的分子靶向药物,彻底改变了晚期GIST治疗的困境。多个前瞻性、随机对照临床试验(ACOSOG Z9000试验、ACOSOG Z9001试验及EORTC试验)相继发现伊马替尼可显著提高中高危型GIST患者术后的无复发生存率。最近,SSG XVIII/AIO试验研究获得了最新结果,发现3年的伊马替尼辅助治疗不论在5年RFS或OS均优于1年的伊马替尼辅助治疗。

Progress in imatinib adjuvant therapy of gastrointestinal stromal tumor

Complete surgical resection(R0) remains the main treatment approach for gastrointestinal stromal tumors(GIST).Unfortunately,over 85% of patients with high-risk GISTs have local tumor relapse and/or metastases even after an R0 resection,with a 5-year recurrence-free survival of only 20%~40%.In the pre-imatinib era,these tumors are also rather resistant to radiotherapy and to conventional chemotherapy.Thus,developing a treatment strategy to reduce tumor recurrence and prolong overall survival(OS) is very impo...